Bioregnum channel feed – Endpoints News

Bioregnum channel feed

Big day looming, Novartis' new CEO Vas Narasimhan readies his jump into a marketing melee

8 years ago

Top 10 pipeline blowups, setbacks and snafus in H2 2017

8 years ago

AstraZeneca gives itself top marks for R&D productivity makeover — but the jury is still out

8 years ago

FDA commissioner Scott Gottlieb just broke a public promise on publishing CRLs — and yes, it matters

8 years ago

Is Roche's pRED finally ready to step out from behind Genentech for its closeup? Probably not

8 years ago

Sanofi's R&D day poses some big challenges as skeptics circle in wake of a Dengvaxia fiasco

8 years ago

Can GSK’s new R&D strategy resuscitate the worst performer in Big Pharma?

8 years ago

After building expectations, the UK’s life sciences plan falls short of the hype

8 years ago

With relocation vote looming, the EMA is openly fretting as cities jockey for attention

8 years ago

Allergan shows how you can destroy your rep and get mobbed by lawmakers in 4 easy steps

8 years ago

Allergan CEO gambles a multibillion-dollar franchise — and his company rep — on a high-stakes bet at an Indian casino op

8 years ago

Preemptive shaming assault on Novartis’ CAR-T pioneer underscores a disconnect on R&D costs

8 years ago

Trump's renewed broadsides on drug pricing didn't even dent biopharma this time

8 years ago

From bombs to bromides? Trump’s jousting with biopharma may well boil down to a handshake on drug prices

8 years ago

8 stars: A look back at ASCO spotlights the top cancer drugs to watch, and 1 to forget

8 years ago

Thumbs up: Cancer drug R&D is exploding, get ready for the pricing debate to follow

8 years ago

Some worthy initiatives out of the FDA fall far short of an effective federal plan to rein in drug prices

8 years ago

A father's plea: The FDA needs to make sure that Juno's lethal disaster isn't repeated

8 years ago

After Kite Pharma stuns analysts with news of a death in lead CAR-T study, safety questions sour launch forecast

9 years ago

Puma's fresh shiner, what the biotech IPO surge tells us, and the trouble with cancer R&D

9 years ago

Scott Gottlieb will push to publish CRLs; Marathon's demise offers the industry a cautionary tale

9 years ago

Don't let a slump in biopharma deals get you down — yet; The controversy on drug prices is taking a toll

9 years ago

Time for biotechies to stand up and be counted on Kendall Square

9 years ago

Scott Gottlieb gave a savvy review of what we can expect at the FDA; When times got rough, a biotech CEO demonstrated real integrity

9 years ago

First page Previous page 10 11 121314 15 16 Next page Last page